Acura Pharmaceuticals Net Profit Margin 2012-2021 | ACUR
Acura Pharmaceuticals net profit margin from 2012 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Acura Pharmaceuticals Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2021-12-31 | $0.00B | 0 | 0.00% |
| 2021-09-30 | $0.00B | 0 | 0.00% |
| 2021-06-30 | $0.00B | $0.00B | -33.33% |
| 2021-03-31 | $0.00B | $0.00B | -33.33% |
| 2020-12-31 | $0.00B | $0.00B | -66.67% |
| 2020-09-30 | $0.00B | $0.00B | -66.67% |
| 2020-06-30 | $0.00B | $0.00B | -25.00% |
| 2020-03-31 | $0.00B | $0.00B | -133.33% |
| 2019-12-31 | $0.00B | $0.00B | -200.00% |
| 2019-09-30 | $0.00B | $0.00B | -400.00% |
| 2019-06-30 | $0.00B | $-0.01B | 0.00% |
| 2019-03-31 | $0.00B | $0.00B | 0.00% |
| 2018-12-31 | $0.00B | $0.00B | 0.00% |
| 2018-09-30 | $0.00B | $-0.01B | 0.00% |
| 2018-06-30 | $0.00B | $-0.01B | 0.00% |
| 2018-03-31 | $0.00B | $-0.01B | 0.00% |
| 2017-12-31 | $0.00B | $-0.01B | -200.00% |
| 2017-09-30 | $0.01B | $0.00B | -28.57% |
| 2017-06-30 | $0.01B | $0.00B | -28.57% |
| 2017-03-31 | $0.01B | $0.00B | -42.86% |
| 2016-12-31 | $0.00B | $-0.01B | -150.00% |
| 2016-09-30 | $0.00B | $-0.01B | -300.00% |
| 2016-06-30 | $0.00B | $-0.01B | -333.33% |
| 2016-03-31 | $0.00B | $-0.01B | -333.33% |
| 2015-12-31 | $0.01B | $-0.01B | -75.00% |
| 2015-09-30 | $0.01B | $-0.01B | -133.33% |
| 2015-06-30 | $0.01B | $-0.01B | -133.33% |
| 2015-03-31 | $0.01B | $-0.01B | -150.00% |
| 2014-12-31 | $0.00B | $-0.01B | -1400.00% |
| 2014-09-30 | $0.00B | $-0.01B | 0.00% |
| 2014-06-30 | $0.00B | $-0.01B | 0.00% |
| 2014-03-31 | $0.00B | $-0.01B | 0.00% |
| 2013-12-31 | $0.00B | $-0.01B | 0.00% |
| 2011-12-31 | $0.02B | $0.01B | 50.00% |
| 2011-06-30 | $0.02B | $0.01B | 40.00% |
| 2011-03-31 | $0.00B | $-0.01B | -1200.00% |
| 2010-12-31 | $0.00B | $-0.01B | -433.33% |
| 2010-09-30 | $0.00B | $-0.01B | -350.00% |
| 2010-06-30 | $0.01B | $-0.02B | -300.00% |
| 2010-03-31 | $0.01B | $-0.02B | -380.00% |
| 2009-12-31 | $0.00B | $-0.02B | -400.00% |
| 2009-09-30 | $0.01B | $-0.02B | -136.36% |
| 2009-06-30 | $0.01B | $-0.01B | -57.14% |
| 2009-03-31 | $0.03B | $0.01B | 20.69% |
| 2008-12-31 | $0.05B | $0.01B | 31.11% |
| 2004-06-30 | $0.00B | $-0.04B | -1075.00% |
| 2004-03-31 | $0.01B | $-0.04B | -740.00% |
| 2003-12-31 | $0.01B | $-0.05B | -816.67% |
| 2003-09-30 | $0.01B | $-0.07B | -1216.67% |
| 2003-06-30 | $0.01B | $-0.07B | -985.71% |
| 2003-03-31 | $0.01B | $-0.07B | -812.50% |
| 2002-12-31 | $0.01B | $-0.06B | -737.50% |
| 2002-09-30 | $0.01B | $-0.03B | -325.00% |
| 2002-06-30 | $0.01B | $-0.02B | -181.82% |
| 2002-03-31 | $0.01B | $-0.02B | -163.64% |
| 2001-12-31 | $0.02B | $-0.01B | -76.47% |
| 2001-09-30 | $0.02B | $-0.01B | -61.11% |
| 2001-06-30 | $0.02B | $-0.01B | -72.22% |
| 2001-03-31 | $0.03B | $-0.01B | -28.00% |
| 2000-12-31 | $0.02B | $-0.01B | -55.00% |
| 2000-09-30 | $0.02B | $-0.02B | -75.00% |
| 2000-06-30 | $0.02B | $-0.02B | -94.12% |
| 2000-03-31 | $0.01B | $-0.02B | -190.91% |
| 1999-12-31 | $0.01B | $-0.02B | -181.82% |
| 1999-09-30 | $0.01B | $-0.02B | -145.45% |
| 1999-06-30 | $0.01B | $-0.02B | -136.36% |
| 1999-03-31 | $0.01B | $-0.01B | -140.00% |
| 1998-12-31 | $0.01B | $-0.01B | -144.44% |
| 1998-09-30 | $0.01B | $-0.02B | -187.50% |
| 1998-06-30 | $0.01B | $-0.01B | -175.00% |
| 1998-03-31 | $0.01B | $-0.01B | -175.00% |
| 1997-12-31 | $0.01B | $-0.02B | -166.67% |
| 1997-09-30 | $0.01B | $-0.02B | -166.67% |
| 1997-06-30 | $0.01B | $-0.02B | -160.00% |
| 1997-03-31 | $0.01B | $-0.02B | -145.45% |
| 1996-12-31 | $0.01B | $-0.02B | -125.00% |
| 1996-09-30 | $0.01B | $-0.01B | -92.86% |
| 1996-06-30 | $0.02B | $-0.01B | -73.33% |
| 1996-03-31 | $0.02B | $-0.01B | -52.94% |
| 1995-12-31 | $0.02B | $0.00B | -15.00% |
| 1995-09-30 | $0.02B | $0.00B | -9.09% |
| 1995-06-30 | $0.02B | $0.00B | -4.17% |
| 1995-03-31 | $0.03B | $0.00B | -4.00% |
| 1994-12-31 | $0.03B | $-0.01B | -20.00% |
| 1994-09-30 | $0.03B | $-0.01B | -26.92% |
| 1994-06-30 | $0.03B | $-0.01B | -34.62% |
| 1994-03-31 | $0.03B | $-0.01B | -42.31% |
| 1993-12-31 | $0.03B | $-0.01B | -33.33% |
| 1993-09-30 | $0.04B | $-0.01B | -17.50% |
| 1993-06-30 | $0.05B | $0.00B | -6.38% |
| 1993-03-31 | $0.05B | $0.00B | 1.89% |
| 1992-12-31 | $0.05B | $0.00B | 4.00% |
| 1992-06-30 | $0.03B | $0.00B | 6.25% |
| 1992-03-31 | $0.03B | $0.00B | 3.45% |
| 1991-09-30 | $0.03B | 0 | 0.00% |
| 1991-06-30 | $0.03B | 0 | 0.00% |
| 1991-03-31 | $0.03B | 0 | 0.00% |
| 1990-12-31 | $0.03B | 0 | 0.00% |
| 1990-09-30 | $0.03B | $0.00B | -4.00% |
| 1990-06-30 | $0.02B | $0.00B | -4.17% |
| 1990-03-31 | $0.02B | $0.00B | -4.55% |
| 1989-12-31 | $0.02B | $0.00B | -4.76% |
| 1989-09-30 | $0.02B | $0.00B | 5.00% |
| 1989-06-30 | $0.02B | $0.00B | 5.26% |
| 1989-03-31 | $0.02B | $0.00B | 5.56% |
| 1988-12-31 | $0.02B | $0.00B | 5.88% |
| 1988-09-30 | $0.01B | 0 | 0.00% |
| 1988-06-30 | $0.01B | 0 | 0.00% |
| 1988-03-31 | $0.01B | 0 | 0.00% |
| 1987-12-31 | $0.01B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |